Scarica l'app Stockscreener
3.56
2.47%
-0.09
Precedente Chiudi:
$3.65
Aprire:
$3.585
Volume 24 ore:
6.47M
Relative Volume:
1.16
Capitalizzazione di mercato:
$1.04B
Reddito:
$194.75M
Utile/perdita netta:
$-51.26M
Rapporto P/E:
-12.71
EPS:
-0.28
Flusso di cassa netto:
$-23.38M
1 W Prestazione:
-10.33%
1M Prestazione:
+43.55%
6M Prestazione:
+92.43%
1 anno Prestazione:
+217.86%
Intervallo 1D:
$3.51
$3.70
Intervallo di 1 settimana:
$3.48
$4.0758
Portata 52W:
$0.80
$4.0758
Akebia Therapeutics Inc Stock (AKBA) Company Profile
Nome
Akebia Therapeutics Inc
Settore
Telefono
617-871-2098
Indirizzo
245 FIRST STREET, CAMBRIDGE, MA
Confronta AKBA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AKBA
Akebia Therapeutics Inc
|
3.56 | 1.04B | 194.75M | -51.26M | -23.38M | -0.28 |
|
ZTS
Zoetis Inc
|
164.33 | 75.76B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.87 | 49.79B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.20 | 46.73B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.99 | 20.38B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
283.35 | 14.70B | 2.99B | 1.21B | 1.13B | 25.06 |
Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-04 | Ripresa | H.C. Wainwright | Buy |
| 2025-04-28 | Iniziato | Leerink Partners | Outperform |
| 2025-04-01 | Iniziato | Jefferies | Buy |
| 2023-11-29 | Ripresa | BTIG Research | Buy |
| 2023-08-28 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2023-05-31 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-03-31 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2022-03-31 | Downgrade | Mizuho | Buy → Neutral |
| 2022-03-31 | Downgrade | Needham | Buy → Hold |
| 2022-03-31 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-03-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-01-29 | Downgrade | JP Morgan | Neutral → Underweight |
| 2019-11-14 | Reiterato | Needham | Buy |
| 2019-08-06 | Reiterato | H.C. Wainwright | Buy |
| 2019-07-11 | Reiterato | H.C. Wainwright | Buy |
| 2019-05-02 | Iniziato | JP Morgan | Overweight |
| 2019-03-20 | Iniziato | Citigroup | Neutral |
| 2018-09-07 | Ripresa | Morgan Stanley | Equal-Weight |
| 2018-08-10 | Reiterato | Needham | Buy |
| 2018-06-06 | Reiterato | H.C. Wainwright | Buy |
| 2017-12-19 | Iniziato | Piper Jaffray | Overweight |
| 2017-12-07 | Iniziato | BTIG Research | Buy |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2017-07-10 | Reiterato | H.C. Wainwright | Buy |
| 2017-04-27 | Reiterato | H.C. Wainwright | Buy |
| 2017-04-27 | Reiterato | Needham | Buy |
| 2016-12-27 | Reiterato | H.C. Wainwright | Buy |
| 2016-12-20 | Reiterato | JMP Securities | Mkt Outperform |
| 2016-11-15 | Iniziato | Aegis Capital | Buy |
| 2016-09-29 | Iniziato | Brean Capital | Buy |
| 2016-03-16 | Reiterato | Needham | Buy |
| 2016-01-21 | Iniziato | Credit Suisse | Neutral |
Mostra tutto
Akebia Therapeutics Inc Borsa (AKBA) Ultime notizie
Akebia Therapeutics expands stock incentive plan - Investing.com Australia
Akebia Therapeutics expands stock incentive plan By Investing.com - Investing.com South Africa
Akebia Therapeutics Approves Stock Plan Amendment at Meeting - TipRanks
Akebia Therapeutics: Stock Is Trading At Fair Value Amid Robust Drug Adoption Into 2026 - Seeking Alpha
Day 7 of Gains Streak for Akebia Therapeutics Stock with 38% Return (vs. 109% YTD) [6/6/2025] - Trefis
H.C. Wainwright Initiates Coverage of Akebia Therapeutics (AKBA) With Buy Rating - MSN
Akebia Therapeutics at Jefferies Conference: Strategic Growth Insights By Investing.com - Investing.com Canada
Organizational Transitions, Patient Enrollment, Initiation of Clinical Programs, Financial Outlook, and Corporate UpdatesA... - ADVFN
Akebia reports mixed results for anemia drug in global study By Investing.com - Investing.com South Africa
Akebia Therapeutics: Finally Showing Potential, But Wait For Q2 Earnings Before Buying - Seeking Alpha
Akebia reports mixed results for anemia drug in global study - Investing.com Australia
Akebia Therapeutics (AKBA) Receives 'Buy' Rating from HC Wainwri - GuruFocus
Akebia (AKBA) Publishes Phase 3 Clinical Trial Analysis | AKBA S - GuruFocus
Akebia Therapeutics Announces Publication of Pre-specified Analyses on Vadadustat from Global Phase 3 Clinical Program in Journal of the American Society of Nephrology - Nasdaq
Vadadustat U.S. Patient Data from Global Phase 3 Clinical - GlobeNewswire
Vadadustat U.S. Patient Data from Global Phase 3 Clinical Program Published in Journal of the American Society of Nephrology - Yahoo Finance
H.C. Wainwright assumes coverage on Akebia Therapeutics stock with buy rating - Investing.com
Akebia (AKBA) Receives Buy Rating with Promising Outlook for Vaf - GuruFocus
Akebia Ther stock soars to 52-week high, hits $3.31 By Investing.com - Investing.com South Africa
Akebia Ther stock soars to 52-week high, hits $3.31 - Investing.com Australia
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule - marketscreener.com
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listi - GuruFocus
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Akebia Therapeutics Expands Team with Strategic New Hires, Grants $415,000 in Stock Options - Stock Titan
Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference 2025 - GlobeNewswire
Kidney Disease Leader Akebia Therapeutics Sets Major Investor Presentation at Jefferies Healthcare Conference - Stock Titan
Akebia’s patent for Anemia therapy gets fresh blood from Court - BananaIP
Akebia Therapeutics Announces Three Poster Presentations at the European Renal Association Congress 2025 - GlobeNewswire
Akebia Unveils Critical Cardiovascular Safety Analysis for Vadadustat in Dialysis Patients at ERA Congress - Stock Titan
Akebia Therapeutics Announces Three Poster Presentations at the European Renal Association ... - Eagle-Tribune
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Northern Trust Corp Has $3.20 Million Stock Position in Akebia Therapeutics, Inc. (NASDAQ:AKBA) - Defense World
Akebia Therapeutics stock soars to 52-week high of $2.91 By Investing.com - Investing.com India
Akebia Therapeutics at H.C. Wainwright Conference: Vafseo’s Strategic Launch By Investing.com - Investing.com Canada
Akebia Therapeutics stock soars to 52-week high of $2.91 - Investing.com Australia
Certain Common Stock of Akebia Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2025. - marketscreener.com
Certain Stock Options of Akebia Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2025. - marketscreener.com
Certain Rights of Akebia Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2025. - marketscreener.com
Certain Warrants of Akebia Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2025. - marketscreener.com
Price T Rowe Associates Inc. MD Has $263,000 Holdings in Akebia Therapeutics, Inc. (NASDAQ:AKBA) - Defense World
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Shares Sold by Voya Investment Management LLC - Defense World
Akebia Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results - GuruFocus
Raymond James Financial Inc. Invests $85,000 in Akebia Therapeutics, Inc. (NASDAQ:AKBA) - Defense World
Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference - GlobeNewswire
Akebia projects Vafseo rollout to double patient access by Q4 2025 - MSN
Akebia Therapeutics, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next - simplywall.st
Akebia Therapeutics First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Mariner LLC Invests $28,000 in Akebia Therapeutics, Inc. (NASDAQ:AKBA) - Defense World
Akebia Therapeutics Inc Azioni (AKBA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.54%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):